Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10304910 | 0.81 | HTR7 (0.44) | SLC6A4SLC6A2SLC6A3KCNH2 | |
| SCHEMBL256798 | 0.81 | MAPT (0.50) | TUBB1SLC6A4SLC6A2SLC6A3NFE2L2 | |
| SCHEMBL166380 | 0.80 | NFE2L2 (0.61) | NFE2L2CA12CA1CA2CA4 | |
| SCHEMBL18472613 | 0.80 | NFE2L2 (0.61) | NFE2L2CA12CA1CA2CA4 | |
| SCHEMBL21345921 | 0.80 | AR (0.46) | TUBB1SLC6A4NFE2L2CA12CA1 | |
| SCHEMBL10304909 | 0.79 | S1PR1 (0.46) | TUBB1SLC6A4SLC6A2SLC6A3NFE2L2 | |
| SCHEMBL16317807 | 0.78 | AR (0.62) | SLC6A4SLC6A2SLC6A3NFE2L2CA12 | |
| SCHEMBL28299621 | 0.78 | NFE2L2 (0.59) | NFE2L2CA12CA1CA2CA4 | |
| SCHEMBL197623 | 0.78 | MEN1 (0.46) | NFE2L2CA12CA1CA2CA4 | |
| SCHEMBL29362946 | 0.78 | MEN1 (0.46) | NFE2L2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4389736-A1 | UREA COMPOUND CONTAINING 2-HETEROAROMATIC RING SUBSTITUTION, PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024032782-A1 | VACCINE ADJUVANTS AND USES THEREOF | JACOBIO PHARMACEUTICALS CO.LTD. (CN) | 2024-02-15 | — | — | WO | disclosed |
| EP-4313962-A1 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. (CN) | 2024-02-07 | — | — | EP | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| EP-3842433-B1 | PYRIDONE-PYRIMIDINE DERIVATIVE ACTING AS KRASG12C MUTEIN INHIBITOR | MEDSHINE DISCOVERY INC (CN) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | ALTAVANT SCIENCES GMBH | 2023-09-19 | — | — | US | disclosed |
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-09-14 | — | — | US | disclosed |
| US-7214682-B2 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-7214682-B2 | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido{1,2-a}pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo{1,2-a}pyrimidin-5(1h)one derivatives | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| WO-2007017752-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS | PFIZER LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2005097112-A2 | ION CHANNEL MODULATORS | WYETH (US) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005087228-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005087750-A1 | ION CHANNEL MODULATORS | WYETH (US) | 2005-09-22 | — | — | WO | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004085408-A1 | 2, 3, 6-TRISUBSTITUTED-4-PYRIMIDONE DERIVATIVES | MITSUBISHI PHARMA CORPORATION (JP) | 2004-10-07 | — | — | WO | disclosed |
| US-6194461-B1 | USEFUL AS MEDICAMENT FOR TREATING RETINAL DEGENERATIVE DISORDERS; ALPHA-(2,4-DIFLUOROPHENYL)-N-T-BUTYLNITRONE, AND CORRESPONDING AMINES WHICH WOULD BE CONVERTED IN VIVO TO THE NITRONE, FOR EXAMPLE | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286961-A1 | SUBSTITUTED TETRAHYDROFURANS AS MODULATORS OF SODIUM CHANNELS | TRPV1, TRPA1, SCN2B | TUBB1 1973/4885SLC6A4 132/4885SLC6A2 173/4885 |
| US-11759462-B2 | Spirocyclic compounds as tryptophan hydroxylase inhibitors | TPH1, TPH2, HTR1A | TUBB1 1803/4885SLC6A4 19/4885SLC6A2 109/4885 |
| US-20230303495-A9 | PYRIDINE OXYNITRIDE, PREPARATION METHOD THEREFOR AND USE THEREOF | SCN11A, HCN4, CACNA1F | TUBB1 2882/4885SLC6A4 198/4885SLC6A2 161/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | TUBB1 980/4885SLC6A4 4832/4885SLC6A2 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.